Ayad Hamdan, MD

Ayad Hamdan, MD, discusses factors to consider when choosing between brentuximab vedotin (Adcetris), doxorubicin, vinblastine, and dacarbazine versus AVD plus bleomycin in patients with Hodgkin lymphoma.

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses a pilot phase I/II trial with brentuximab vedotin (Adcetris) plus chemotherapy in patients with HIV-associated Hodgkin lymphoma.